Moderna, $MRNA, Q2-25. Results: 📊 EPS: -$2.13 🟢 💰 Revenue: $142M 🟢 📈 Net Loss: $0.8B 🔎 Moderna lowered its 2025 revenue forecast due to shipment delays but reported three FDA approvals and promising Phase 3 flu vaccine data.
$MRNA (-8.0% pre) Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K. https://t.co/U6QX20GhvL
Moderna’s second-quarter loss was narrower than Wall Street expected as the struggling biotech company cuts costs to offset waning sales of its Covid shot https://t.co/xDgt1BCeZy
Moderna Inc. reported second-quarter revenue of $142 million, beating Wall Street’s $112.9 million estimate, while a loss of $2.13 a share was narrower than the predicted $2.97. The Cambridge, Massachusetts-based company posted a net loss of $825 million as Covid-19 vaccine demand continued to slow. Sales fell 41% from a year earlier, with Spikevax generating $114 million—$88 million in the United States and $26 million overseas. Cash, cash equivalents and investments stood at $7.5 billion on 30 June; the company still expects to finish 2025 with roughly $6 billion. Moderna trimmed the high end of its 2025 revenue forecast by $300 million, citing a delay in contracted shipments to the U.K. It now projects full-year revenue of $1.5 billion to $2.2 billion, with 40%–50% of that total arriving in the third quarter and the remainder in the fourth. Facing persistent weakness in its Covid franchise, the company said it will deepen cost-cutting by a further $400 million and reduce its global workforce by about 10%, bringing projected 2025 operating expenses to $5.9–$6.1 billion. Management pointed to three recent U.S. Food and Drug Administration approvals—including a next-generation Covid shot and an expanded indication for its RSV vaccine—along with positive Phase 3 data for its seasonal flu candidate, as reasons for optimism about medium-term growth.